GMP Uncorked at Boxyard RTP

Overview

Join GrayMatter Partners and co-sponsors PQMS & Fluor for the next stop in our GMP Uncorked Networking Event series at Boxyard RTP. We’re looking forward to an evening of great conversations, food, drinks, and a unique atmosphere in the heart of RTP.

Whether you’re looking to reconnect with familiar faces, meet new industry peers, or simply unwind and network with others across the life sciences community, this will be a great opportunity to build relationships in a casual and welcoming setting. If you’re in life sciences, this is the place to be!

https://luma.com/GMP-Uncorked

June 25, 2026 5:00pm - June 25, 2026 7:00pm

Boxyard RTP
900 Park Offices Dr,
Durham, NC 27713

FREE

Networking

https://luma.com/GMP-Uncorked

June 24, 2026

Concept to Commercialization: An Owner’s Perspective on the Modern Pharma Project Lifecycle

This event brings together life sciences leaders to discuss the realities of navigating today’s pharmaceutical projects, from early planning and design through startup, validation, and commercial readiness.

Panelists will discuss owner-side perspectives on project execution, operational readiness, collaboration, and the evolving challenges shaping modern life sciences facilities and manufacturing environments.

Featured Panelists:

September 17, 2026

UNC Women's Health Research Symposium

The inaugural Women's Health Multidisciplinary Research Symposium, to be held at UNC, will foster interdisciplinary connections, collaboration, and knowledge sharing among trainees and faculty passionate about women’s health research.

This symposium is hosted by the Women’s Health Multidisciplinary Consortium (WHMC) and the Department of Pathology and Laboratory Medicine and supported by the Center for Women’s Health Research and the School of Medicine’s Department of Obstetrics & Gynecology.

June 18, 2026

United Therapeutics receives FDA clearance for xenoheart clinical trial

United Therapeutics Corporation, a public benefit corporation with co-headquarters in Research Triangle Park, has received U.S. Food and Drug Administration (FDA) clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart xenoheart derived from a pig.